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OBJECTIVES: To determine the cost-effectiveness of treatment with caffeine com-
pared to placebo for apnea of prematurity, in infants with birth-weight less than 1250
grams, using data from the multicenter international Caffeine for Apnea of Prematu-
rity (CAP) trial (New Engl J Med, 2006 354: 20). METHODS: We undertook a ret-
rospective economic evaluation of the cost per survivor without Bronchopulmonary 
Dysplasia (BPD), using individual patient data from clinical trial. We included direct 
medical costs either to the insurance payer or the hospital but excluded costs to parents
and society, such as lost productivity. We multiplied local resource utilization data 
from the clinical trial, including days of ventilation, type of surgery or drug dosage, 
by unit costs for each resource. Unit costs were derived from two separate databases 
of Canadian costs for similar patient populations. We used a price of $0.10 per mg
of generic caffeine citrate for our base case analysis. All costs were expressed in 2008
Canadian dollars. The time horizon for this analysis extended to ﬁ rst discharge home. 
RESULTS: The mean cost per infant was $117,577 in the caffeine group and $126,078 
in the placebo group (difference of $8,501, p  0.0025). Cost-effectiveness analysis 
showed caffeine to be a dominant therapy: in 100% of 1000 bootstrap replications 
of the analysis, caffeine-treated infants had simultaneously better outcomes and lower
mean costs. These results were robust to a ten-fold increase in the cost of caffeine.
CONCLUSIONS: In comparison to placebo, caffeine therapy for apnea of prematurity 
in infants less than 1250 grams is economically appealing. Extension of the time 
horizon for this cost-effectiveness analysis to 18 to 21 months corrected age is 
currently in progress.
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OBJECTIVES: Premenstrual dysphoric disorder (PMDD), a more severe form of 
Premenstrual Syndrome (PMS), is reported to affect between 3–8% of reproductive 
aged women. While PMDD has received increased attention in recent years, the cost-
effectiveness of treatments for PMDD remains unknown. This study objective was 
to assess the cost-effectiveness of treatment strategies for PMDD from a payer’s per-
spective. METHODS: A decision-analytic model was developed to evaluate the cost-
effectiveness of four medications with FDA-approved indication for treatment of 
PMDD; YAZ (DRSP 3 mg/EE), Sarafem (ﬂ uoxetine), Zoloft (sertaline), and Paxil
CR (paroxetine). Direct costs included medication and physician visits for a 6-month 
treatment period. Clinical outcomes were assessed using treatment success, failure,
and discontinuation rates. Medication costs were generated based on AWP of branded 
products. Physician visit costs were obtained from a claims database study of PMDD
patients and the Agency for Healthcare Research and Quality. Clinical outcomes 
probabilities were derived from published clinical trials on PMDD. The incremental 
cost-effectiveness ratio (ICER) was calculated using the difference in costs and percent-
age of successfully treated patients, allowing switching due to treatment failure at 3-
months. Deterministic and probabilistic sensitivity analyses were used to assess the 
impact of uncertainty in parameter estimates. RESULTS: YAZ was shown to be the 
most cost-effective strategy, dominating both Zoloft and Paxil. The estimated ICER 
of Sarafem relative to YAZ was $4385. The cost-effectiveness of YAZ relative to 
Sarafem was maintained even if the cost or success rate of YAZ were varied within
50% of the base case value, whereas a change in cost-effective strategy (from YAZ to 
Sarafem) was identiﬁ ed at a threshold value of $3450. This threshold is more than
double the value associated with the most costly treatment. CONCLUSIONS: Yaz was
more cost-effective than Sarafem and was both less costly and more effective compared 
to Paxil and Zoloft.
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OBJECTIVES: In Spain, tobacco consumption levels among children are high, more 
than 46% (latest data available). In this scenario, a school-based tobacco prevention 
programme (ITES) was developed, following PRECEDE model by Green LW et al., 
which intends to inﬂ uence on factors that determine our behaviour, such as values and 
attitudes to smoking. The objetive is to assess cost-effectiveness ratio of ITES in
Spanish high schools. METHODS: A decision tree model was developed. One branch 
represented the scenario where ITES was implemented in high schools, while the other 
branch represented the scenario without ITES. Analysis was performed from the per-
spective of the health care system and the time horizon was student’s lifetime. Model’s 
parameters were obtained from a pilot study in high schools in Canary Islands and
from scientiﬁ c literature. Direct and indirect lifetime costs were included. The selected 
effectiveness measure was life years gained (LYG) and discount rate was 3%. Stochas-
tic and multivariate sensitivity analysis was performed, and acceptability curves were
calculated. RESULTS: The ICER is €44,911 /LYG, and IC [€44,972/LYG; €44,848/
LYG]. The average incremental cost is €22,061,641 and IC [€22,406,222; €21,717,059]. 
The average incremental effectiveness is 491.23 /LYG and IC [484.23 LYG; 498.22
LYG]. The probability of right decision for a willingness to pay of €9000/LYG is 95%. 
CONCLUSIONS: The introduction of ITES in Spanish high schools offers a favour-
able cost-effectiveness ratio. The introduction of ITES in Spanish high school is a good
way to save money and gain LY.
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OBJECTIVES: To assess cost-effectiveness ratio of MS/MS screening for PKU and
MCADD in Spanish communities. METHODS: A decision tree model was developed. 
One branch represented the scenario where MS/MS was implemented for PKU and 
MCADD screening, while another branch represented the scenario without MS/MS
technology (no screening for MCADD). Analysis was performed from the Health
System perspective and the time horizon was newborn’s lifetime. Main model param-
eters were obtained from a Spanish newborn screening program, scientiﬁ c literature, 
and expert’s recommendations. The selected effectiveness measure was years of 
life gained (LYG) and discount rate was 3%. Stochastic and multivariate sensitivity
analysis was performed, and acceptability curves were calculated. RESULTS: Case of 
decentralized screening programs along Communities, and about 90–100 thousand 
births per year (/Y); the incremental cost-effectiveness ratio (ICER) is €5936/LYG and 
CI [€5866/LYG; €5986/LYG]. However, when births number is around 5,000/Y, ICER 
is €30,554 /LYG and CI [€30,236/LYG; €30,877/LYG]. For a willingness to pay 
around €30,000/LYG, probabilities of right decision of each scenario are 100% and
43.28% respectively. CONCLUSIONS: The introduction of MS/MS neonatal screen-
ing for PKU and MCADD offers favourable cost-effectiveness ratio. Cost-effectiveness
ratio becomes better with growing number of annual screenings with MS/MS, remain-
ing more or less constant on 30–40 thousand infants/Y.The ﬁ ndings of this report 
support MS/MS introduction for PKU and MCADD screening in Spanish Communi-
ties, when alive newborns number is superior to 5000/Y.
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OBJECTIVES: To perform a comparative cost-effectiveness analysis from the Brazilian
Public Health System’s perspective of the standard treatment with goserelin acetate of 
only patients with deep endometriosis conﬁ rmed by videolaparoscopy versus empirical 
treatment with goserelin acetate of all patients with chronic pelvic pain and suspected 
deep endometriosis. METHODS: To determine the local experience of standard treat-
ment and empiric treatment, it was conducted a specialist consult with a gynecologist 
from a public institution, with large experience in endometriosis treatment. It was 
developed an analytic decision model to estimate the cost effectiveness ratio of empiric 
treatment versus pattern treatment with goserelin depot 3.6 mg every four weeks, 
during six months. Efﬁ cacy rates were obtained from published literature. The model
includes only direct costs, obtained from Ambulatory and Hospital Information
System and Price Database of Brazilian Ministry of Health. The outcome used was 
time until symptoms improvement. RESULTS: The cost-effectiveness analysis revealed 
that the empiric therapy with goserelin lead to a reduction of time until improvement 
of symptoms of 3 months, and lower cost with a reduction of US$1662 (1US$ 
R$1.6428), when compared to the pattern treatment with previous videolaparoscopy. 
CONCLUSIONS: Empiric therapy of endometriosis using goserelin acetate seems to 
be a cost-saving alternative in the Brazilian Public Health System scenario.
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OBJECTIVES: To examine the cost-effectiveness of thermal balloon endometrial abla-
tion (TBEA) and levonorgestrel intrauterine system (LNG-IUS) one year after treat-
ment in a group of patients with idiopathic menorrhagia in a public hospital in Hong 
Kong. METHODS: The subjects were patients who were previously recruited in a 
randomized clinical trial to compare their health status after treatment with TBEA or 
LNG-IUS. The study design was a retrospective review of case history of the group 
of patients who participated in the earlier study. Study endpoint was at one year after 
treatment with a satisfactory control of bleeding. Cost items collected included medica-
tions, laboratory procedures, duration of hospital stays, transfusions, use of emergency 
room/intensive care unit facilities, outpatient clinic follow-ups, visits to private doctors 
